ProtAffin Company Profile
ProtAffin AG is a pre-clinical stage ProtAffin has used the CellJammer®
Pre-clinical stage biologics
biotech company based in Austria in discovery technology to create a
platform company in Austria
modern office/laboratory facilities. Our pipeline of four products.
16 employees are focussed on
Our lead product PA401 is in pre-
designing & developing innovative
● Focus clinical development. PA401 is a
protein-based products for chronic
modified version of human interleukin-
Developing anti-inflammatory inflammatory diseases. We also are
8 and it works by coating the inflamed
proteins which target glycans developing programs in oncology.
endothelium with an inert layer of
on cell surfaces
protein by binding to glycans (i.e.
GAGs). We believe that targeting
protein-GAG interactions directly has
● Platform Technology
advantages over targeting such
CellJammer® discovery proteins with monoclonal antibodies
technology for targeting (mAbs) or GAG derivatives. A patent
protein-glycan interactions protecting PA401 has been granted in
using modified human the EU in 2009.
PA401 is an anti-
inflammatory based on
human IL-8 in pre-clinical ProtAffin is pioneering a new class of
development, Orphan Drug biologics, which are protein therapeutics
designation granted by FDA targeting glycans driving inflammatory Finance
and EMEA processes and cancer. While all other ProtAffin raised a €14 Series B
biologics and antibody companies target financing in April 2009 led by Atlas
other proteins, ProtAffin is developing Venture and SR One. The Company
● Indications the paradigm that specific glycans are a has also received €2m non-dilutive
Various chronic and acute rich source of druggable targets for the research support from AWS and FFG
inflammatory diseases, with Pharma and Biotech Industry. Our in Austria and raised a €4m Series A
early stage oncology approach of modifying human proteins round in 2007, led by Aescap.
discovery programs. to bind disease associated glycans with
higher affinity is applicable to many of
the best known targets in inflammation
● Financing and oncology. Outlook
€14m Series B financing in Chemokines rely on protein-glycan ProtAffin will progress is lead product
April 2009 co-led by Atlas interactions for efficiently driving cellular PA401 through pre-clinical
Venture and SR One Ltd. inflammation in diseases such as lung development and plans a Phase I trial
€4m Series A round in 2007 inflammation and rheumatoid arthritis. within the funding period of Series B
led by Aescap Ventures. ProtAffin is initially applying its discovery financing. We will nominate further
technology to chemokines for the programs for pre-clinical development
development of anti-inflammatory and in 2010.
● Management oncology products.
Jason Slingsby, CEO
Contact: ProtAffin Biotechnologie AG
Andreas Kungl, CSO Impulszentrum Graz-West, Reininghausstrasse 13a
A-8020 Graz, Austria
Tel: +43 316 382 541
April 2009 E-mail: email@example.com